INTRODUCTION

More than 10 million people worldwide suffer from Parkinson’s disease (PD). The pathological hallmark of PD is the loss of dopamine neurons in substantia nigra pars compacta associated with the accumulation of misfolded and aggregated α-synuclein (α-syn) into intraneuronal inclusions (called Lewy bodies) (Kalia, 2019; Kim et al., 2014; Stefanis, 2012). These days, due to the absence of disease-modifying treatments for PD, there is a great desire to develop new drugs for the management of PD that are not only therapeutic but can also prevent the initiation of the disease or either delay or stop its progression (Davis et al., 2019; DeMaagd & Philip, 2015). One of the current
approaches to prevent disease progression include targeting the formation and promoting intracellular degradation of α-syn aggregates. Multiple lines of evidence suggested that the modulation of α-syn aggregation, oligomerization, fibrillation and propagation to reduce its toxicity emerged as an important therapeutic target for slowing or halting disease progression (Brundin et al., 2017; Kalia, 2019). Moreover, the overexpression of E3 ubiquitin ligase Nedd4, which enhances α-syn ubiquitination and leading to α-syn clearance, is sufficient to reduce neurotoxicity in vivo (Boland et al., 2018; Davies et al., 2013; Yuan et al., 2019).

The budding yeast *Saccharomyces cerevisiae* is one of the organisms used in drug discovery. It can be highly useful in the first-line screening of potential active compounds (Franssens et al., 2013; Tenreiro & Outeiro, 2010; Zimmermann et al., 2018). It is a powerful model organism for PD because its cellular processes are highly conserved with those of higher eukaryotes. Other advantages are its rapid growth and the existence of comprehensive genetic tools (Franssens et al., 2013; Tenreiro & Outeiro, 2010). As described above, *S. cerevisiae* has been widely used as a model organism with which to gain insights into α-syn toxicity. Previous reports suggested that α-syn-related effects, such as proteasome impairment, vesicle trafficking dysfunction, and reactive oxygen species generation, can be efficiently mimicked in *S. cerevisiae* cells, which do not endogenously express the α-syn ortholog. Additionally, the heterologous expression of human α-syn results in intracellular α-syn accumulation and growth defect in an α-syn dose-dependent manner (Franssens et al., 2009; Petroi et al., 2012; Soper et al., 2011). These findings have made *S. cerevisiae* a valuable cell model for studying the physiological and pathological features of α-syn and for screening active compounds that alleviate α-syn toxicity.

*Saccharomyces cerevisiae* Rsp5 is an essential homolog to the E6-AP carboxyl terminus (HECT)-type E3 ubiquitin ligase that is highly conserved with the mammalian Nedd4-family E3 ubiquitin ligases (Wang et al., 1999). Rsp5 was recently shown to affect a variety of cellular events, such as intracellular trafficking, signal transduction and quality control of the plasma membrane and cytosolic proteins through the interaction and ubiquitination of diverse substrate proteins (Dunn & Hicke, 2001; Jarmoszewicz et al., 2012; Shiga et al., 2014). Rsp5 is structured in three domains: an amino-terminal C2 domain, three substrate-recognizing WW domains and a carboxyl-terminal catalytic HECT domain (Wang et al., 1999). It was previously reported that the *rsp5*<sup>A401E</sup> mutant, having a point mutation in the nonconserved Ala residue at position 401 with Glu of the WW3 domain, showed much more sensitivity to stresses that cause protein misfolding, such as toxic amino acid analogues, high growth temperature in a rich medium and ethanol, than the wild-type strain (Hoshikawa et al., 2003). Wijayanti et al. (2015) showed that the overexpression of α-syn in *S. cerevisiae* cells led to growth inhibition, especially in the *rsp5*<sup>A401E</sup> mutant, indicating that the *rsp5*<sup>A401E</sup> mutant is also hypersensitive to α-syn accumulation. These results suggested that Rsp5 is involved in the maintenance of stress-induced abnormal proteins through a degradation or repair system (Haitani et al., 2006; Haitani & Takagi, 2008; Hiraishi et al., 2009). Therefore, biological/chemical agents or compounds that could complement the stress sensitivity of the *rsp5*<sup>A401E</sup> mutant might be promising as drug candidates, which exert their effect via the ubiquitin/proteasome system.

To discover novel drug candidates, it is essential to establish a simple, robust and inexpensive assay method. The assay should also serve as a tool for high-throughput screening to assess large sets of compound libraries (Inglese et al., 2007; Szymanski et al., 2012). Resazurin (7-hydroxy-3H-phenazin-3-one-10-oxide) is a tetrazolium-based, weakly fluorescent, nontoxic and water-soluble dye that can be reduced by cellular metabolic activity to the highly fluorescent resorufin (Bowling et al., 2012; Csepregi et al., 2018). Several intracellular oxidoreductases, such as NADH dehydrogenase and diaphorase, are responsible for the reduction of resazurin to resorufin during cell viability assays (Bowling et al., 2012; Rolón et al., 2006). Therefore, resazurin has been successfully used to determine cell viability and proliferation of micro-organism for drug discovery (Lescat et al., 2019; Sangkaew et al., 2020; Uzarski et al., 2017).

In this study, we developed a novel yeast-based assay system to search for molecules that could alleviate the human α-syn-induced cytotoxicity of multidrug-sensitive strains with the *rsp5*<sup>A401E</sup> background. A yeast-integrating plasmid carrying the *rsp5*<sup>A401E</sup> gene was introduced into a drug-sensitive strain, allowing us to observe the sensitivities of the resultant strains to various stresses, such as high temperature, toxic amino acid analogue and α-syn. Subsequently, the yeast-based assay system with resazurin was optimized to be used as a high-throughput platform. This system was also validated using two known compounds, baicalein, and ampicillin, for sensitivity and specificity.

## MATERIALS AND METHODS

### Strains, plasmids, culture media and chemicals

Yeast strains used in this study are listed in Table 1. All yeasts strains were *S. cerevisiae* with the CAY29 (Andreasson & Ljungdahl, 2002) or BY25929 (obtained from Yeast Genetic Resource Center, Japan) background. The *rsp5*<sup>A401E</sup>-mutant strains (HT01) in the CAY29 background were previously constructed (Haitani et al., 2009).
A multidrug-sensitive yeast strain BY25929, in which four multiple drug resistance genes (YRS1, YRR1, PDR1 and PDR3) were deleted, was obtained from Yeast Genetic Resource Center, Osaka, Japan. To construct strain TK01 (the rsp5A401E mutant with the BY25929 background) (Figure 1), the integrating plasmid pRS406 (URA3) was used for two-step replacements of the wild-type RSP5 with rsp5A401E-mutant allele (Gray et al., 2005). For over-expression of human α-syn, a galactose-inducible multi-copy plasmid pYES2 α-syn GFP was used (Wijayanti et al., 2015).

The culture medium used for the growth of S. cerevisiae was a nutrient-rich yeast extract-peptone-dextrose (YPD) medium (1% yeast extract, 2% peptone and 2% glucose) and synthetic complete (glucose or raffinose) medium lacking uracil [SC-Ura or SR-Ura] (2% glucose or raffinose, 0.67% yeast nitrogen base without amino acids (Difco Laboratories) and 1× amino acid mix lacking uracil]. An alternative synthetic complete medium, synthetic complete (galactose) medium lacking uracil (SG-Ura) that contains 2% galactose as the carbon source instead of glucose was used to induce the overexpression of α-syn.

Table 1: Yeast strains used in this study

| Strain | Mating type | Genotype | Source or reference |
|--------|-------------|----------|---------------------|
| CAY29  | MATa        | ura3-52  | Andreasson and Ljungdahl (2002) |
| BY25929| MATa        | trp1-1 leu2-3, 112 his3-11, 15 ura3-1 ade2-1 can1-100 yrs1::HIS3 yrr1::TRP1 pdr1::hisG pdr3::hisG | Yeast Genetic Resource Center, Japan |
| HT01   | MATa        | CAY29 rsp5A401E | Haitani et al. (2009) |
| TK01   | MATa        | BY25929 rsp5A401E | This study |

Figure 1: Schematic diagram of the genetically modified strain TK01 (pYES2 α-syn GFP). Strain TK01 was hypersensitive to various drugs and stresses since the ABC transporter genes were deleted, leading to the accumulation of drug in the cell, and the rsp5A401E mutant allele was introduced in its chromosomal RSP5 locus by two-step gene replacement method. In order to construct yeast strain expressing human α-syn, strain TK01 was transformed with pYES2 α-syn GFP. Generally, human α-syn is a plasma membrane-bound protein, which can be ubiquitinated by Rsp5 and finally degraded via the ubiquitin-mediated protein degradation. Accumulation of aggregated α-syn triggers cytotoxicity, leading to cell death. The effect was more obvious in the yeast rsp5A401E mutant than in the RSP5 strain.
For L-azetidine-2-carboxylic acid (AZC) sensitivity, a synthetic minimal (glucose) medium (SD) (0.67% yeast nitrogen base without amino acids, 2% glucose and only essential amino acids) with or without 1 mmol l⁻¹ AZC (TCI Chemicals) was used.

All chemicals used were of analytical grade or higher. Resazurin sodium salt (Sigma-Aldrich) was dissolved in 1× phosphate buffer saline to make a stock solution, and subsequently filtered using a syringe with 0.22-µm membrane. The prepared resazurin solution was covered to prevent exposure to light and was stored at 4°C for no longer than 2 weeks. For compounds used in system validation, baiacalein (kindly provided by Dr. Boon-ek Yingyongnarongkul, Ramkhamhaeng University) and ampicillin sodium salt (Sigma-Aldrich) were freshly prepared in 100% dimethyl sulfoxide, water respectively.

**Yeast transformation**

Yeast transformation was performed by lithium acetate method (Schiestl & Gietz, 1989). To enhance the transformation efficiency, 50 µg of deoxyribonucleic acid sodium salt from salmon testes (Sigma-Aldrich) was added. For two-step gene replacement method, strain BY25929 was transformed with 5 µg of linearized pRS406-rsp5<sup>A401E</sup> (Haitani & Takagi, 2008). Yeast transformants were selected on SC-Ura and then some of them were subjected to counter selection in the medium containing uracil and 5-fluoroorotic acid (5-FOA) (Zymo Research) (Akada et al., 2006). Only cells which have popped out the URA3 marker by recombination between homologous duplicated sequences could survive and grow. In order to identify transformants containing the <i>rps5</i><sup>A401E</sup> mutation, DNA sequencing was performed. For construction of the strain overexpressing α-syn, the <i>rps5</i><sup>A401E</sup> mutant was transformed with pYES2 α-syn GFP.

**Growth assay**

Spot-dilution assays were performed using overnight culture grown in SR medium, a synthetic minimal (raffinose) medium (0.67% yeast nitrogen base without amino acids, 2% raffinose and only essential amino acids). Aliquots from such cultures were adjusted to A<sub>600 nm</sub> =0.08 or 1 × 10<sup>6</sup> cells per ml with sterilized water. Five-fold serial dilutions were made in sterilized water, and aliquots (5 µl) of all yeast suspensions were spotted onto the assay medium. After the liquid in each spot was absorbed, the plates were incubated under assay conditions, and then the resulting plates were photographed. For assay of AZC sensitivity, the cell suspensions were spotted onto SD medium supplemented with 1 mmol l⁻¹ AZC, and the plates were incubated at 30°C for 2–3 days. In parallel, high temperature sensitivity of yeast cells was tested on YPD medium. After spotting cell suspensions, the plates were incubated at 37°C for 30 h and further incubated at 30°C for 2–3 days. The sensitivity against α-syn was assessed using yeast cells overexpressing α-syn. Overnight cultured cells in SR-Ura medium were spotted onto SG-Ura (for α-syn overexpression) and SC-Ura (for α-syn shutoff) media. After 2–3 days incubation at 30°C, the plates were photographed.

**Resazurin yeast-based cell viability assay**

Resazurin yeast-based assay was performed using black polystyrene, nontissue cultured treated, sterile, low binding 96-well microtiter plates (Thermo Fisher Scientific) and fluorescent signal of resorufin was measured using an Ensight Multimode Microplate Reader (PerkinElmer). Excited wavelength was set on 540 with 590 nm as emission wavelength. The experimental parameters were optimized, including resazurin concentration, initial cell densities and length of incubation of yeast indicator strain with resazurin, for assessing cell viability of the yeast strain. The resazurin reduction test was carried out as follows. Briefly, a total of 50 µl of yeast cultured SR-Ura at twice the desired final yeast density was added to wells of a 96-well black microtiter plate. Subsequently, 50 µl of inducible SG-Ura medium supplemented with or without test compound at twice the desired concentration was added to each well for a final volume of 100 µl. To correct for autofluorescence, the blank was prepared for all treatments by substitution of the cell suspensions with the growth medium. The assay plate was incubated at 30°C for 24 h. After incubation, 10 µl of resazurin at a desired concentration in 1× PBS was added to each well. Yeast cell viability was expressed as relative fluorescence unit (RFU) with top scanning mode. RFU of yeast-generated resorufin was recorded immediately after the resazurin dosing to all wells, and then again in 30 min period until RFU in each well without the test compound decreased. To define the relationship between the compound concentration in the sample suspension and intensity of the resorufin fluorescence, resazurin reduction curves were plotted. The minimal effective concentration was defined as the lowest concentration of the test compound that alleviates human α-syn toxicity and so accelerated the resazurin reduction.

**Statistical analysis**

All assays were performed triplicates on at least two independent occasions. Two-way ANOVA analysis was
performed for the appropriate data. All statistical data were analysed using the statistical and graphical functions of the GRAPHPAD PRISM 5.02 package (GraphPad Software). $p < 0.05$ was accepted as the level of statistical significance.

**RESULTS**

**Effects of AZC and high temperature on the growth phenotype of the $rsp5^{A401E}$-mutant strains**

In a previous study, the $rsp5^{A401E}$ mutant strain showed hypersensitivity to various stresses that induce protein misfolding in the cell, such as the toxic proline analogue AZC and high temperature (Hoshikawa et al., 2003). To enhance sensitivity to test compounds, the drug-hypersensitive strain BY25929 lacking the multidrug-resistant genes was used to replace the $rsp5^{A401E}$-mutant allele with its chromosomal $RSP5$ by a two-step gene replacement method (Figure 1). The resultant strain (the $rsp5^{A401E}$ mutant of BY25929) was designated as strain TK01 (Figure 1). To further examine its growth phenotype, serially diluted cell suspensions of strains BY25929 ($RSP5$) and TK01 ($rsp5^{A401E}$) were spotted onto SD medium supplemented with or without 1 mmol l$^{-1}$ AZC. High growth sensitivity to 1 mmol l$^{-1}$ AZC on the assay medium was clearly observed in strain TK01 in comparison with strain BY25929 (Figure 2a). To assess sensitivity to high temperature, both strains were pretreated to high temperature at 37°C for 30 h, and further incubated at 30°C for 48 h. Strain TK01 grew on YPD medium at 30°C at a rate similar to that of strain BY25929; however, after pretreatment at 37°C, this mutant (TK01) showed a high temperature growth defect compared to the wild-type strain (BY25929) (Figure 2b). Both of the growth phenotypes observed indicated the characteristics of the mutant (Hoshikawa et al., 2003).

**Effect of $\alpha$-syn on the growth phenotype of the $rsp5^{A401E}$-mutant strain**

To evaluate whether the $rsp5^{A401E}$ mutant is more sensitive to $\alpha$-syn than the wild-type $RSP5$, strains BY25929 and TK01 were transformed with either empty vector pYES2 or a plasmid harbouring $\alpha$-syn (pYES2 $\alpha$-syn GFP). The $\alpha$-syn was expressed under the control of a strong inducible GAL1 promoter. The transformants were grown onto either SC-Ura (no $\alpha$-syn expression) or SG-Ura (induction of $\alpha$-syn expression). As clearly shown in Figure 3 (right panel), the overexpression of $\alpha$-syn from the 2µ plasmid led to a severe growth defect. Similar results were obtained in the case of another genetic background yeast strains, CAY29 and HT01 (Figure 3). It appears that the $\alpha$-syn sensitivity of strain TK01 was not as clear as that of strain HT01. However, both strains TK01 (pYES2 $\alpha$-syn GFP) and HT01 (pYES2 $\alpha$-syn GFP) were further evaluated in order to set up a resazurin yeast-based assay system, and were compared for drug sensitivity.

**Setting up the resazurin yeast-based assay to search for compounds alleviating $\alpha$-syn toxicity**

Metabolic activity may differ among yeast strains, so the concentration of resazurin should be optimized. Strains HT01 (pYES2 $\alpha$-syn GFP) and TK01 (pYES2 $\alpha$-syn GFP)
were plated in 96-well plates at various cell concentrations (between $1.6 \times 10^3$ and $1 \times 10^6$ cells per ml). Different concentrations of resazurin were added, starting from 0.05 to 0.4 mmol l$^{-1}$. The results showed that resazurin reduction was positively proportional to the resazurin concentration (from 0.05 until 0.2 mmol l$^{-1}$) (Figure 4). However, this gradual increase in fluorescence intensity was limited to 0.2 mmol l$^{-1}$ since, at 0.4 mmol l$^{-1}$, the resazurin reduction showed a greater decrease than that of 0.2 mmol l$^{-1}$, indicating that the optimal resazurin concentration of these strains was 0.2 mmol l$^{-1}$.

Because resazurin reduction is affected by time and cell concentration, it is important to determine the initial cell concentration and resazurin incubation time. Strains HT01 and TK01, carrying either empty vector pYES2-GFP or pYES2 α-syn GFP, were cultured in SG-Ura at different initial cell concentrations and were then incubated for 16–18 h. Resazurin solution was added according to the optimal concentration obtained. The reduction of resazurin was recorded over 300 min. The kinetics of resazurin conversion to resorufin in cell suspensions of the four strains are summarized in Figure 5, which depicts the resazurin reduction curves for various initial cell concentrations. In this experiment, strains HT01 (pYES2 α-syn GFP) (Figure 5a) and TK01 (pYES2 α-syn GFP) (Figure 5c) were used as assay strains to determine the effect of compound on alleviating α-syn toxicity. Yeast strains harbouring the empty vector (Figure 5b,d), which showed faster reduction kinetics than the assay strains, served as positive growth controls. Figure 5a shows that assay strain HT01, at a starting cell concentration of less than $5 \times 10^4$ cells per ml, displayed significant lags in RFUs. Cell concentrations of

![Figure 3](image1.png)

**Figure 3** Effect of α-syn on the growth phenotype of the $rsp5^{A401E}$ mutant strains. Spotting assay was performed to assess the effect on growth following overexpression of α-syn. Cell suspension of five-fold serial dilutions of the yeast transformants harbouring plasmid either α-syn GFP or empty vector were spotted onto selective medium plates containing 2% glucose (no α-syn expression) or 2% galactose (α-syn overexpression) starting with equal number of cells ($1 \times 10^8$ cells per ml), and the plates were incubated at 30°C for 2 days.

![Figure 4](image2.png)

**Figure 4** Effects of resazurin and cell concentrations on fluorescence intensity in the $rsp5^{A401E}$-mutant strains. Various cell concentrations ($1 \times 10^6$, $2 \times 10^5$, $4 \times 10^4$, $8 \times 10^3$ and $1.6 \times 10^3$ cells per ml) of strains HT01 (pYES2 α-syn GFP) (a) and TK01 (pYES2 α-syn GFP) (b) were added into wells of a 96-well plate. Different resazurin concentrations were then added, ranging from 0.05 to 0.4 mmol l$^{-1}$. After 90 min incubation, fluorescence intensity was measured and expressed as relative fluorescence unit (RFU). The values are means ± standard deviations (SD) of results from three independent experiments. Symbols indicate the resazurin concentrations at 0.05 (*), 0.1 (△), 0.2 (□) and 0.4 (○) mmol l$^{-1}$. Statistical significances are indicated by the p-value (**p < 0.001, 0.2 mmol l$^{-1}$ vs. 0.05, 0.1, 0.4 mmol l$^{-1}$).
5 × 10^5 and 1 × 10^6 cells per ml produced maximal RFU relatively quickly (180 and 150 min respectively). However, the resazurin kinetics of strain HT01 (pYES2 α-syn GFP) showed almost no difference compared to that of strain TK01 (pYES2-α-syn GFP) (Figure 5a,b). Therefore, starting cell concentrations of 5 × 10^4 to 1 × 10^5 cells per ml already showed significant RFUs in the presence of any growth. Also, the optimal cell concentrations of the HT01 background strains were between 5 × 10^4 and 1 × 10^5 cells per ml, and the optimal incubation time with resazurin was longer than 300 min.

The TK01 background strains showed faster reduction kinetics than the HT01 background strains (Figure 5c, 5d vs 5a, 5b). Initial cell concentrations of the TK01 background strains between 5 × 10^5 and 1 × 10^6 cells per ml almost immediately reduced resazurin to resorufin, with a steep increase in fluorescence intensity, whereas lower cell concentrations started to increase the amount of resorufin with slower kinetics of resazurin reduction. However, starting cell concentrations of less than 5 × 10^4 cells per ml displayed significant lags in growth. Starting cell concentrations between 5 × 10^2 and 1 × 10^5 cells per ml yielded a significant increase in RFUs over time compared to the other cell concentrations and thus were chosen as the optimal range of cell concentrations (Figure 5c,d). According to the optimal concentrations chosen, the incubation time with resazurin should be monitored for up to 240 min for strain TK01 (pYES2 α-syn GFP) as the yeast indicator strain for the assay (Figure 5c).

Validation of the resazurin yeast-based assay system

Usually test compounds are dissolved in 100% (v/v) DMSO solvent, so the DMSO concentration must be optimized in order to avoid the cytotoxic effect on yeast cells. This study, a final concentration of DMSO at 0.5% (v/v) was chosen to minimize its cytotoxicity (Figure S1).

To validate the resazurin yeast-based assay for the isolation of compounds that alleviate α-syn toxicity, we determined the effects of baicalein, which inhibits α-syn oligomerization (Hu et al., 2016), at various concentrations (25–0.04 µmol l⁻¹). For strain HT01 (pYES2 α-syn GFP), no protective effect of baicalein was found against α-syn toxicity at any concentrations tested (Figure 6a). In contrast, strain TK01 (pYES2 α-syn GFP) treated with 5 µmol l⁻¹ baicalein showed a significant increase in RFUs compared to the untreated control (0 µmol l⁻¹) (Figure 6c). However, RFUs from cells treated with lower concentrations (<5 µmol l⁻¹) of baicalein were not statistically different (Figure 6c). The strains harbouring the empty vector treated with any concentration of baicalein served as indicator cells for the cytotoxicity of the compound at the concentrations tested. At 25 µmol l⁻¹, but not at 5 µmol l⁻¹, baicalein caused toxicity to all tested strains (Figure 6a–d).

Furthermore, another compound, ampicillin, a β-lactam antibiotic that inhibit bacterial cell wall synthesis, was also tested for the specificity of the assay system. Strain TK01, carrying either pYES2 α-syn GFP or the empty vector treated with various concentrations of ampicillin showed a significant increase in RFUs compared to the untreated control (0 µmol l⁻¹) (Figure 6c). The strains harbouring the empty vector treated with any concentration of ampicillin served as indicator cells for the cytotoxicity of the compound at the concentrations tested. At 25 µmol l⁻¹, but not at 5 µmol l⁻¹, ampicillin caused toxicity to all tested strains (Figure 6a–d).
vector, were incubated in assay medium containing ampicillin at concentrations ranging from 25 to 1.56 mmol l\(^{-1}\) for 24 h. The kinetic of resazurin reduction were monitored. The results showed that ampicillin treatments did not exhibit any statistically significant differences from the untreated control, suggesting that ampicillin does not have a role in alleviating \(\alpha\)-syn toxicity. Treatment of cells with a high concentration of ampicillin (25 mmol l\(^{-1}\)) resulted in a cytotoxic effect in both yeast strains (Figure 6e and f; Figure S2).

Next, to compare the sensitivity of strains TK01 (pYES2 \(\alpha\)-syn GFP) and BY25929 (pYES2 \(\alpha\)-syn GFP) was incubated in assay medium containing the desired concentrations of baicalein. The kinetics of resazurin conversion into resorufin in cell suspensions of both strains are summarized in Figure 7, which depicts the resazurin reduction curves for strains TK01 and BY25929 in various concentrations of baicalein. The cytotoxicity of baicalein was observed at 12.5–25 \(\mu\text{mol l}^{-1}\) with low resazurin reduction rates. Strain BY25929 (pYES2 \(\alpha\)-syn GFP), treated with either 3.13 or 6.25 \(\mu\text{mol l}^{-1}\) baicalein, exhibited a significantly higher RFU than the untreated control (Figure 7a). Interestingly, strain TK01 (pYES2 \(\alpha\)-syn GFP), treated with either 3.13 or 6.25 \(\mu\text{mol l}^{-1}\) baicalein, revealed much higher reduction kinetics than strain BY25929 (pYES2 \(\alpha\)-syn GFP), treated with the same amount of baicalein, showing a significantly higher RFU than the untreated control (Figure 7c). These findings indicate that in the BY25929 background strain, the \(\text{RSP5}^{\text{A401E}}\) mutant strain (TK01) was more sensitive to a compound that alleviate \(\alpha\)-syn toxicity than the wild-type \(\text{RSP5}\) strain (BY25929) (Figure 7c vs 7a).

To compare the sensitivity of our developed assay system with that of the conventional growth monitoring method using optical density measurement at 660 nm, a 96-well clear microplate containing either strain BY25929 (pYES2 \(\alpha\)-syn GFP) or TK01 (pYES2 \(\alpha\)-syn GFP) treated with various concentrations of baicalein (25–0.39 \(\mu\text{mol l}^{-1}\)) was incubated at 30\(^\circ\)C for 24 h. Then, the growth of yeast cells in each well was measured at OD\(_{660}\) nm. There were no statistically significant differences in growth between the cells treated with 0.39–6.25 \(\mu\text{mol l}^{-1}\) baicalein and the untreated control (Figure 7b and 7d). However, a significant decrease in the growth of cells treated with 12.5 and 25 \(\mu\text{mol l}^{-1}\) baicalein were observed, indicating the cytotoxic effect of baicalein at such concentrations (Figure 7b and 7d). These results showed that the assay based on a fluorescent signal of

**FIGURE 6** Effects of baicalein and ampicillin on alleviating \(\alpha\)-syn toxicity in the resazurin yeast-based assay system. Strains HT01 (pYES2 \(\alpha\)-syn GFP) (a), HT01 (pYES2-GFP) (b), TK01 (pYES2 \(\alpha\)-syn GFP) (c) and TK01 (pYES2-GFP) (d) were grown in SG-Ura supplemented with baicalein at final concentrations 0 (○), 0.04 (○), 0.2 (●), 1 (●), 5 (●) and 25 (●) \(\mu\text{mol l}^{-1}\) as indicated. Strains TK01 (pYES2 \(\alpha\)-syn GFP) (e) and TK01 (pYES2-GFP) (f) were grown in SG-Ura supplemented with ampicillin at final concentrations 0 (○), 1.56 (○), 3.13 (●), 6.25 (●), 12.5 (●) and 25 (●) mmol l\(^{-1}\) as indicated. The 96-well plates were incubated at 30\(^\circ\)C for 16–18 h. Resazurin was added to a final concentration at 0.2 mmol l\(^{-1}\). Fluorescence intensity was measured over 100 min. The values are means ± standard deviations (SD) of results from three independent experiments. For (c), statistical significances are indicated by the \(p\)-value (***\(p < 0.001\), 5 \(\mu\text{mol l}^{-1}\) vs. 0 \(\mu\text{mol l}^{-1}\)).
resorufin was much more sensitive than the cell turbidity determination (Figure 7a, 7c vs. 7b, 7d).

Together, these findings supported that the resazurin yeast-based assay system using the rps5<sup>A401E</sup> mutant strain TK01 (pYES2 α-syn GFP) was an effective assay system with high sensitivity and specificity.

**DISCUSSION**

*Saccharomyces cerevisiae* is one of the most fantastic model organisms due to its easy handling and genetic availability. Expression of α-syn in yeast cells disrupted vesicle trafficking, ion homeostasis and mitochondrial function (as in neurons), leading to growth inhibition (Flight, 2013). This finding was based on the assumption that compounds that protect yeast cells from α-syn-mediated toxicity would be “positively” detectable by their ability to promote the growth of cells suffering from α-syn toxicity. We thus developed a novel yeast-based assay to search for compounds alleviating α-syn toxicity by utilizing resorufin, a highly sensitive fluorescent growth reduced product, to measure the output in 96-well plate format. This is based on the finding that *S. cerevisiae* cells have thick cell walls and bear ABC transporters with xenobiotic efflux capacity, which are obstacles to drug screening for test compounds entering and accumulating inside the cells (Sangkaew et al., 2018). To overcome this problem, in this study a multidrug-sensitive yeast strain BY25929, from which were deleted four so-called *MDR1* genes encoding for ABC transporters, was used to facilitates the uptake of compounds in the drug screening (Sangkaew et al., 2018).

Rsp5p, the Nedd4 ortholog in *S. cerevisiae* is also able to bind α-syn and efficiently ubiquitinates α-syn leading to the promotion of α-syn degradation and cell protection from α-syn-induced toxicity in *S. cerevisiae* (Braun, 2015). Interestingly, Hoshikawa et al. (2003) reported that the rps5<sup>A401E</sup> mutant showed much higher sensitivity to the toxic proline analogue AZC compared to the wild-type strain. This AZC-associated phenotype was involved in the deficient ubiquitination of the general amino acid permease Gap1, leading to the stabilization of Gap1 on the plasma membrane (Hoshikawa et al., 2003). After α-syn expression was shut off in the rps5<sup>A401E</sup> mutant, the intracellular level of α-syn was found to decrease, suggesting that the mutant still could ubiquitinate α-syn (unpublished results). When α-syn was overexpressed, the rps5<sup>A401E</sup> mutants (HT01 and TK01 strains) were more sensitive to α-synuclein than their respective *RSP5<sup>WT</sup>* strains (Figure 3).
To determine the viability of yeast cells expressing α-syn in a high-throughput format, we set up a resazurin reduction assay, which is a reliable, sensitive and easy-to-use fluorescent assay, using two different background yeast strains, HT01 (pYES2 α-syn GFP) and TK01 (pYES2 α-syn GFP). Resazurin is an oxidation-reduction dye that turns into a fluorescent compound (resorufin) after a reduction process caused by viable cells (Bowling et al., 2012; Zare et al., 2015). A previous study suggested that the assay using resazurin to monitor both viability and growth of cells was more sensitive than the agar plate assay (Sangkaew et al., 2018). The fluorescence intensity measured is proportional to cell growth and can be quantified by fluorescence spectroscopy (Ibáñez Escribano et al., 2012). Several experimental parameters, such as the resazurin concentration, starting cell concentration and time of incubation with the redox dye, were optimized as follows. A concentration of 0.2 mmol l$^{-1}$ of resazurin was chosen for further experiments starting cell concentration and time of incubation with the resazurin incubation periods since resazurin reduction periods required to determine the effect of the test compound was dissolved in DMSO at a final concentration of 0.5% (v/v) (Figure S1). Baicalein is a typical flavonoid compound isolated from traditional Chinese herb Scutellaria baicalensis Georgi. It exerts neuroprotective effects in PD model through antioxidant and anti-inflammatory activity (Mu et al., 2009; Wang et al., 2013). Simultaneously, previous research reported that baicalein could inhibit the formation of α-syn oligomers, and disaggregate existing oligomer of α-syn in vitro (Zhu et al., 2004). In PD cellular model, baicalein is demonstrated to be an effective inhibitor of α-syn aggregation and protect cells from α-syn oligomer-induced cytotoxicity (Hu et al., 2016; Lu et al., 2011). Our results showed that baicalein prevented α-syn oligomer-induced cytotoxicity only in strain TK01 (pYES2 α-syn GFP) (Figure 6c) and not in strain HT01 (pYES2 α-syn GFP) (Figure 6a). These results indicate that the drug-sensitive BY25929 background showed higher sensitivity to baicalein than the CAY29 background. This may be due to greater accumulation of baicalein inside TK01 (pYES2 α-syn GFP) cells than the other. Baicalein concentrations of 0.04–5 µmol l$^{-1}$ showed no cytotoxicity except at the concentration of 25 µmol l$^{-1}$ (Figure 6a–d). The irrelevant compound ampicillin, an antibiotic used to prevent and treat bacterial infections via inhibition of bacterial cell wall synthesis (Chambers & Sachdeva, 1990), did not significantly increase the RFU signal of strain TK01 (pYES2 α-syn GFP) (Figure 6e) including HT01(pYES2 α syn GFP) (Figure S2) when compared to that of the untreated control (0 µmol l$^{-1}$). However, high concentrations of ampicillin showed cytotoxicity with significantly lower RFU signals (Figure 6e and f and Figure S2). These results assured the specificity of the developed assay system.

Baicalein was also used to compare the sensitivity to α-syn toxicity between the rps5<sup>AA401E</sup> and RSP5<sup>WT</sup> strains with the BY25929 background. Strain TK01 (pYES2 α-syn GFP) treated with baicalein exhibited faster and higher reduction kinetics than strain BY25929 (pYES2 α-syn GFP) treated at 3.13 µmol l$^{-1}$ baicalein (Figure 7c vs 7a). In contrast, when baicalein-treated cells were measured for growth using conventional optical density at OD$_{660}$, no positive effect of baicalein was detected (Figure 7b and...
The highly sensitive assay of our resazurin yeast-based screening system was further confirmed by using strain TK01 (pYES2 α-syn GFP) as an indicator strain could detect baicalein at concentrations as low as 3.13 µmol l⁻¹, which was lower than that in previous report that showed that baicalein inhibited α-syn fibrillation at 5–100 µmol l⁻¹ using an in vitro Thioflavin T (ThT) assay (Zhu et al., 2004).

Taken together, these results suggest that TK01 (pYES2 α-syn GFP) is sensitive and specific enough to serve as an indicator strain for this resazurin yeast-based assay system. Furthermore, the toxicity of the test compound was confirmed during screening using strain TK01 (pYES2-GFP). This study has successfully established a novel yeast-based screening system for compounds that can restore growth inhibition of α-syn. Baicalein alleviated α-syn toxicity by restoring the growth of the indicator strain. For pharmacological application, our method can be used as a primary drug screening system for the discovery of potential active compounds for neurodegenerative diseases especially PD. The candidate compounds may either efficiently suppress α-syn aggregation or enhance ubiquitin-dependent degradation. However, to validate the compounds identified in our yeast-based system, a human cell PD model need to be further used.

ACKNOWLEDGEMENTS
This work was supported by the Asahi Glass Foundation to CY, Rachadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University to AS, the 90th Anniversary of Chulalongkorn University Fund to CY-TK, and by Global Collaborative Program (2019-2021), Nara Institute of Science and Technology, Nara, Japan, to HT. The authors thank Boon-ek Yingyongnarongkul, PhD, Department of Chemistry, Faculty of Science, Ramkhamhaeng University, Thailand for providing baicalein. The authors also thank the Yeast Genetics Resource Center, Japan for providing strain BY25929.

CONFLICT OF INTEREST
The authors confirm that there are no conflicts of interest associated with the present work.

AUTHOR CONTRIBUTIONS
A.S., H.T. and C.Y. conceived the study and designed the experiments. A.S., T.K. and R.T. performed the experiments. A.S., H.T. and C.Y. analysed the data and wrote the manuscript. All authors read and approved the final manuscript.

ETHICAL APPROVAL
This article does not contain any studies with human participants or animals by the authors.

REFERENCES
Akada, R., Kitagawa, T., Kaneko, S., Toyonaga, D., Ito, S., Kakihara, Y. et al. (2006) PCR-mediated seamless gene deletion and marker recycling in Saccharomyces cerevisiae. Yeast, 23, 399–405.
Andreonsson, C. & Ljungdahl, F.O. (2002) Receptor-mediated endoproteolytic activation of two transcription factors in yeast. Genes & Development, 16, 3158–3172.
Boland, B., Yu, W.H., Corti, O., Mollereau, B., Henriques, A., Bezard, E. et al. (2018) Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nature Reviews Drug Discovery, 17, 660–688.
Bowling, T., Mercer, L., Don, R., Jacobs, R. & Nare, B. (2012) Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis. International Journal for Parasitology: Drugs and Drug Resistance, 2, 262–270.
Braun, R.J. (2015) Ubiquitin-dependent proteolysis in yeast cells expressing neurotoxic proteins. Frontiers in Molecular Neuroscience, 8, 8.
Brundin, P., Dave, K.D. & Kordower, J.E.H. (2017) Therapeutic approaches to target alpha-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. Journal of Infectious Diseases, 161, 1170–1176.
Csepregi, R., Lemli, B., Kunsági-Máté, S., Szente, L., Oszegi, T., Nemeti, B. & et al. (2018) Complex formation of resorufin and resazurin with B-cyclodextrins: can cyclodextrins interfere with a resazurin cell viability assay? Molecules 23, 382.
Davies, S., Hallett, P., Moens, T., Smith, G., Rocha, E., Kim, H.T. et al. (2013) Enhanced ubiquitin-dependent degradation by Ned4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson’s disease. Neurobiology of Diseases, 64, 79–87.
Davis, T.L., Rafferty, M., Lyons, K., Ramirez-Zamora, A., Gao, H., Wu, S. et al. (2019) Parkinson’s disease treatments and outcomes: US v non-US patients. Movement Disorders, 34, S246.
DeMaagd, G. & Philip, A. (2015) Parkinson’s disease and its management: part 5: Treatment of nonmotor complications. P&T, 40, 838–846.
Dunn, R. & Hicke, L. (2001) Domains of the Rsp5 ubiquitin-protein ligase required for receptor-mediated and fluid-phase endocytosis. Molecular Biology of the Cell, 12, 421–435.
Flight, M. (2013) Yeast cells reveal new target for Parkinson’s disease. Nature Reviews Drug Discovery, 13, 19.
Franssens, V., Boelen, E., Jayamani, A., Vanhelmont, T., Buettner, S. & Winderickx, J. (2009) Yeast unfolds the road map toward -synuclein-induced cell death. Cell Death and Differ, 17, 746–753.
Franssens, V., Bynens, T., Van den Brande, J., Vandermeeren, K., Verduyckt, M. & Winderickx, J. (2013) The benefits of humanized yeast models to study Parkinson’s disease. Oxidative Medicine and Cellular Longevity, 2013, 760629.
Gray, M., Piccirillo, S. & Honigberg, S.M. (2005) Two-step method for constructing unmarked insertions, deletions and allele substitutions in the yeast genome. *FEMS Microbiology Letters*, 248, 31–36.

Haitany, Y., Nakata, M., Sasaki, T., Uchida, A. & Takagi, H. (2009) Engineering of the yeast ubiquitin ligase Rsp5: isolation of a new variant that induces constitutive inactivation of the general amino acid permease Gap1. *FEMS Yeast Research*, 9, 73–86.

Haitany, Y., Shimoi, H. & Takagi, H. (2006) Rsp5 regulates expression of stress proteins via post-translational modification of Hsf1 and Msn4 in *Saccharomyces cerevisiae*. *FEBS Letters*, 580, 3433–3438.

Haitany, Y. & Takagi, H. (2008) Rsp5 is required for the nuclear export of mRNA of HSF1 and MSN2/4 under stress conditions in *Saccharomyces cerevisiae*. *Genes to Cells*, 13, 105–116.

Hiraishi, H., Shimada, T., Ohtsu, I., Sato, T.A. & Takagi, H. (2009) The yeast ubiquitin ligase Rsp5 downregulates the alpha subunit of nascent polypeptide-associated complex Egd2 under stress conditions. *FEBS Journal*, 276, 5287–5297.

Hoshikawa, C., Shichiri, M., Nakamori, S. & Takagi, H. (2003) A non-conserved Aa401 in the yeast Rsp5 ubiquitin ligase is involved in degradation of Gap1 permease and stress-induced abnormal proteins. *Proceedings of the National Academy of Sciences of the USA*, 100, 11505–11510.

Hu, Q., Uversky, V.N., Huang, M., Kang, H., Xu, F., Liu, X. et al. (2016) Baicalein inhibits alpha-synuclein oligomer formation and prevents progression of alpha-synuclein accumulation in a rotenone mouse model of Parkinson's disease. *Biochimica et Biophysica Acta*, 1862, 1883–1890.

Ibáñez Escribano, A., Meneses-Marcel, A., Tugores, J., Nogal-Ruiz, J.J., Arán, V., Escario, J.A. & et al. (2012) Validation of a modified fluorimetric assay for the screening of trichomonacidal drugs. *Memorias do Instituto Oswaldo Cruz*, 107, 637–643.

Inglese, J., Johnson, R.L., Simeonov, A., Xia, M., Zheng, W., Austin, C.P. et al. (2007) High-throughput screening assays for the identification of chemical probes. *Nature Chemical Biology*, 3, 466–479.

Jarmoszewicz, K., Lukasiak, K., Riezman, H. & Kaminska, J. (2012) Rsp5 ubiquitin ligase is required for protein trafficking in *Saccharomyces cerevisiae COPI* mutants. *PLoS One*, 7, e39582.

Kalía, L. (2019) Alpha-synuclein as a potential biomarker and therapeutic target for Parkinson's disease. *Journal of Neurochemistry*, 150, 35.

Kim, W.S., Kagedal, K. & Halliday, G.M. (2014) Alpha-synuclein biology in Lewy body diseases. *Alzheimer's Research & Therapy*, 6, 73.

Lescat, M., Poirel, L., Tinguely, C. & Nordmann, P. (2019) A resazurin reduction-based assay for rapid detection of polymyxin resistance in *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *Journal of Clinical Microbiology*, 57, e01563–e1618.

Lu, J.H., Ardah, M.T., Durairajan, S.S., Liu, L.F., Xie, L.X., Fong, W.F., et al. (2011) Baicalein inhibits formation of alpha-synuclein oligomers within living cells and prevents Abeta peptide fibrillation and oligomerisation. *Chembiochem*, 12, 615–624.

Mu, X., He, G., Cheng, Y., Li, X., Xu, B. & Du, G. (2009) Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. *Pharmacology Biochemistry and Behavior*, 92, 642–648.

Petroi, D., Popova, B., Taheri-Talesh, N., Irieger, S., Shahpasandzadeh, H., Zweckstetter, M. et al. (2012) Aggregate clearance of alpha-Synuclein in *Saccharomyces cerevisiae* depends more on autophagosome and vacuole function than on the proteasome. *Journal of Biological Chemistry*, 287, 27567–27579.

Rólón, M., Vega, C., Escario, J.A. & Barrio, A. (2006) Development of resazurin microtiter assay for drug testing of *Trypanosoma cruzi* epimastigotes. *Parasitology Research*, 99, 103–107.

Sangkaew, A., Krungkrai, J. & Yompakdee, C. (2018) Development of a high throughput yeast-based screening assay for human carbonic anhydrase isozyme II inhibitors. *AMB Express*, 8, 124.

Sangkaew, A., Samritsakulchai, N., Sanachai, K., Rungrothmongkol, T., Chavasiri, W. & Yompakdee, C. (2020) Two flavonoid-based compounds from *Murraya paniculata* as novel human carbonic anhydrase isozyme II inhibitors detected by a resazurin yeast-based assay. *Journal of Microbiology and Biotechnology*, 30, 552–560.

Schiestl, R.H. & Gietz, R.D. (1989) High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier. *Current Genetics*, 16, 339–346.

Shiga, T., Yoshida, N., Shimizu, Y., Suzuki, E., Sasaki, T., Watanabe, D. et al. (2014) Quality control of plasma membrane proteins by *Saccharomyces cerevisiae* Ned4-like ubiquitin ligase Rsp5p under environmental stress conditions. *Eukaryotic Cell*, 13, 1191–1199.

Soper, J.H., Kehm, V., Burd, C.G., Bankaitis, V.A. & Lee, V.M. (2011) Aggregation of alpha-synuclein in *S. cerevisiae* is associated with defects in endosomal trafficking and phospholipid biosynthesis. *Journal of Molecular Neuroscience*, 43, 391–405.

Stefanis, L. (2012) Alpha-Synuclein in Parkinson's disease. *Cold Spring Harbor Perspectives in Medicine*, 2, a009399.

Szmyanz, P., Markowicz, M. & Mikiciuk-Olasik, E. (2012) Adaptation of high-throughput screening in drug discovery-toxicological screening tests. *International Journal of Molecular Sciences*, 13, 427–452.

Tenneiro, S. & Outeiro, T.F. (2010) Simple is good: yeast models of neurodegeneration. *FEMS Yeast Research*, 10, 970–979.

Travnickova, E., Mikula, P., Opraal, J., Bohacova, M., Kubac, L., Kimmer, D. et al. (2019) Resazurin assay for assessment of antimicrobial properties of electrospun nanofiber filtration membranes. *AMB Express*, 9, 1–11.

Uzarski, J.S., DiVito, M.D., Wertheim, J.A. & Miller, W.M. (2017) Essential design considerations for the resazurin reduction assay to noninvasively quantify cell expansion within perfused extracellular matrix scaffolds. *Biomaterials*, 129, 163–175.

Wang, G.L., Yang, J. & Huibregtse, J.M. (1999) Functional domains of the Rsp5 ubiquitin-protein ligase. *Molecular and Cellular Biology*, 19, 342–352.

Wang, Y., Yu, H.T., Pu, X.P. & Du, G.H. (2013) Baicalein prevents 6-hydroxydopamine-induced mitochondrial dysfunction in SH-SY5Y cells via inhibition of mitochondrial oxidation and up-regulation of DJ-1 protein expression. *Molecules*, 18, 14726–14738.

Wijayanti, I., Watanabe, D., Oshiro, S. & Takagi, H. (2015) Isolation and functional analysis of yeast ubiquitin ligase Rsp5 variants that alleviate the toxicity of human alpha-synuclein. *Journal of Biochemistry*, 157, 251–260.
Yuan, N.N., Cai, C.Z., Wu, M.Y., Zhu, Q., Su, H., Li, M. et al. (2019) Canthin-6-one accelerates alpha-synuclein degradation by enhancing UPS activity: drug target identification by CRISPR-Cas9 whole genome-wide screening technology. *Frontiers in Pharmacology*, 10, 16.

Zare, M., Amin, M.M., Nikaeen, M., Bina, B., Pourzamani, H., Fatehizadeh, A. et al. (2015) Resazurin reduction assay, a useful tool for assessment of heavy metal toxicity in acidic conditions. *Environmental Monitoring and Assessment*, 187, 276.

Zhu, M., Rajamani, S., Kaylor, J., Han, S., Zhou, F. & Fink, A.L. (2004) The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. *Journal of Biological Chemistry*, 279, 26846–26857.

Zimmermann, A., Hofer, S., Pendl, T., Kainz, K., Madeo, F. & Carmona-Gutierrez, D. (2018) Yeast as a tool to identify anti-aging compounds. *FEMS Yeast Research*, 18, foy020.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Sangkaew, A., Kojornna, T., Tanahashi, R., Takagi, H. & Yompakdee, C. (2022) A novel yeast-based screening system for potential compounds that can alleviate human α-synuclein toxicity. *Journal of Applied Microbiology*, 132, 1409–1421. https://doi.org/10.1111/jam.15256